Enovis Co. (NYSE:ENOV) Shares Bought by Benjamin Edwards Inc.

Benjamin Edwards Inc. lifted its stake in shares of Enovis Co. (NYSE:ENOV) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,205 shares of the company’s stock after acquiring an additional 1,610 shares during the period. Benjamin Edwards Inc.’s holdings in Enovis were worth $755,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ENOV. Quadrant Capital Group LLC grew its holdings in shares of Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after buying an additional 239 shares in the last quarter. Amalgamated Bank increased its stake in Enovis by 1.0% in the fourth quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock valued at $1,136,000 after purchasing an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. lifted its position in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after buying an additional 300 shares during the period. Arizona State Retirement System grew its holdings in Enovis by 2.6% in the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock valued at $711,000 after buying an additional 414 shares during the period. Finally, UMB Bank n.a. boosted its position in shares of Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ENOV. JMP Securities reduced their target price on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Friday. Needham & Company LLC decreased their target price on shares of Enovis from $64.00 to $57.00 and set a “buy” rating for the company in a research note on Friday.

Enovis Price Performance

Shares of ENOV stock opened at $33.05 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. Enovis Co. has a 1-year low of $29.32 and a 1-year high of $53.84. The firm has a fifty day moving average of $35.27 and a two-hundred day moving average of $41.59. The firm has a market cap of $1.89 billion, a P/E ratio of -15.09 and a beta of 1.79.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $558.83 million for the quarter, compared to analysts’ expectations of $558.80 million. During the same period last year, the business posted $0.50 earnings per share. The firm’s revenue for the quarter was up 8.2% on a year-over-year basis. As a group, research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.